Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 18/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098690 | 1.00 | AVPR1A (0.49) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL1116640 | 0.89 | HSP90AA1 (0.51) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL1116644 | 0.89 | HSP90AA1 (0.51) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2099296 | 0.88 | AVPR1A (0.47) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL1116648 | 0.88 | AVPR1A (0.47) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2097261 | 0.88 | HSP90AA1 (0.48) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2097262 | 0.88 | HSP90AA1 (0.48) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2098760 | 0.88 | HSP90AA1 (0.50) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2099089 | 0.88 | HSP90AA1 (0.50) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL2097924 | 0.88 | HSP90AA1 (0.50) | AVPR1AHSP90AA1HSP90AB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 317/4885HSP90AA1 529/4885HSP90AB1 411/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 311/4885HSP90AA1 376/4885HSP90AB1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.